# Village-Integrated Eye Worker Trial II (VIEW II) Extension

> **NIH NIH UG1** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $1,448,874

## Abstract

PROJECT SUMMARY/ABSTRACT
 The World Health Organization estimates that 80% of blindness worldwide is avoidable. However, in
resource-limited settings progressive eye diseases such as glaucoma, diabetic retinopathy (DR), and age-related
macular degeneration (AMD) often go undiagnosed until it is too late. New approaches that detect progressive
eye diseases before they cause irreversible vision loss could help reduce visual impairment of communities. One
such approach is community-based eye disease screening. The Village Integrated Eye Workers Trial II (VIEW
II) is an ongoing cluster-randomized trial in which communities in Nepal receive visual acuity screening and are
subsequently randomized to receive either a community-based eye disease screening intervention consisting of
optical coherence tomography (OCT) and intraocular pressure (IOP) assessment, or to no intervention. The goal
of the screening intervention is to detect cases of glaucoma, diabetic retinopathy, and age-related macular
degeneration—all of which are progressive and cause irreversible vision loss if left untreated—and refer these
cases to the local eye hospital for management. A door-to-door census is performed four years after starting the
screening intervention to determine the effectiveness of screening for reducing vision impairment relative to
communities not receiving the screening intervention.
 This is a proposal for the extension of the VIEW II trial, maintaining the original randomization and
continuing the same screening intervention in the study clusters except that fundus photography is also included
in the screening intervention and that the targeted age group is expanded to those ≥50 years. The specific aims
of the proposal are (1) to determine if the screening intervention is effective for preventing vision loss at the
community level over 7 years, (2) to compare text messages versus community volunteers for improving linkage
to care, and (3) to determine the natural history of OCT measurements over time in a population-based study.
Glaucoma, DR, and AMD are slowly progressive diseases, and given interruptions to study activities caused by
the COVID-19 pandemic, the originally planned 4-year endpoint in the original VIEW II trial may not be long
enough to observe the full effect of the screening intervention. Extending the trial will provide a more accurate
assessment of any benefit of screening. Extending the trial also allows for repeated OCTs in a population-based
sample, providing much needed data on the natural history of OCT parameters to help clinicians better determine
what constitutes progression. This research is significant because it will provide the strongest type of evidence
to guide national eye health programs – results from a randomized controlled trial. Ultimately, this trial will benefit
blindness prevention programs worldwide in deciding how to allocate limited resources to optimally detect eye
disease.

## Key facts

- **NIH application ID:** 10934924
- **Project number:** 1UG1EY036346-01
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Jeremy David Keenan
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,448,874
- **Award type:** 1
- **Project period:** 2024-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10934924

## Citation

> US National Institutes of Health, RePORTER application 10934924, Village-Integrated Eye Worker Trial II (VIEW II) Extension (1UG1EY036346-01). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10934924. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*